News for Immunic, Inc. (IMUX)

IMUX stock's drop appears to be an overreaction, given positive disability progression data and clean safety profile. Click to read why IMUX is a Strong Buy.

PR NewswireNEW YORK, June 3, 2025 NEW YORK, June 3, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company

Immunic, Inc. (IMUX) secures $65 million from an oversubscribed public offering. Potential for an additional $130 million if all warrants are exercised.

PR NewswireNEW YORK, June 2, 2025 NEW YORK, June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeli

On May 29, 2025, Immunic (IMUX) witnessed a significant development as D. Boral Capital announced adjustments in its target price for the stock. Analyst Jason K

Analysts at D. Boral Capital have adjusted their price target for Immunic (IMUX), lowering it to $10 from $17. This decision follows the company's successful pr

On May 23, 2025, B. Riley Securities analyst William Woods reiterated the "Buy" rating for Immunic (IMUX), while adjusting the price target from USD 6.00 to USD

In a recent update, B. Riley revised its price target for Immunic (IMUX) from $6 to $5 while maintaining a Buy rating on the stock. This adjustment comes on the

PR NewswireLUND, Sweden, May 13, 2025 LUND, Sweden, May 13, 2025 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA) today announced that

Brookline has increased its price target for Immunic (IMUX) from $19 to $22, maintaining a Buy rating on the stock. This decision follows the company's release

**media[600316,600317,600318,600319,600320,600321]**

PR NewswireNEW YORK, March 3, 2025 NEW YORK, March 3, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipe

PR NewswireNEW YORK, Feb. 26, 2025 ”“ Vidofludimus Calcium's Activation of Nurr1 Reduces Neuronal Loss and Injury Directly and Indirectly By Decreasing Mi

On December 31, 2024, JANUS HENDERSON GROUP PLC (Trades, Portfolio) executed a significant transaction involving the reduction of its holdings in Immunic Inc (I

Overview of the Recent Transaction On December 31, 2024, Avidity Partners Management LP (Trades, Portfolio) made a significant move by acquiring an additional 7

PR NewswireNEW YORK, Jan. 7, 2025 ”“ Top-Line Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis Expected in April

PR NewswireNEW YORK, Nov. 26, 2024 NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pip

Immunic, Inc. (NASDAQ:IMUX) Q3 2024 Earnings Conference Call November 7, 2024 8:00 AM ETCompany ParticipantsJessica Breu - Vice President Investor Relations...

Release Date: November 07, 2024For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Immunic Inc